RE:RE:RE:RE:RE:Adstiladrin data shown at end of Nov at big UroOncology meet The poster for Adstiladrin was released and it didn't really give a lot of specifics beyond what we know.
https://qr.apothecomcx.com/review/qrcodes/150204661-18/150204661_18_36_Month_Followup_CIS_Poster.pdf
I hope TLT points out to the FDA that the panel recommended:
- 40%-50% at 6 months (note that they don't list 3m CR or CR at any time)
- 30% for 18-24 months, with the lower bound of the 95% confidence interval excluding 20%
So far, adstiladrin has failed this
- 6m: 40.7% ( a bare pass)
- 24m: 19.4% (lower bound of 10% !)
Keytruda failed this too.
As such, no approved drug at this target....yet.
Ruvidar coming through.